Biosensor's Novel Drug-Coated Stent First For U.S. Clinical Trial
This article was originally published in PharmAsia News
Singapore's Biiosensors International said it has received U.S. FDA approval for a clinical trial of its drug-eluting stent without having to test the first-of-its-kind device on at least 100 patients.
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.